Swiss-based CRISPR Therapeutics has submitted an application to European regulators to begin the first industry-sponsored clinical trial of a CRISPR-based gene-editing therapy. The proposed study would test CTX001, a treatment designed for patients with sickle cell disease and beta-thalassemia, with a target start date of 2018.
The filing marks a significant step for the gene-editing field, which has moved rapidly from laboratory concept to potential bedside application. In an interview with Wired, CRISPR Therapeutics CEO Samarth Kulkarni described the submission as a milestone not only for his company but for the broader scientific community. He noted that just three years ago, CRISPR-based treatments were often dismissed as science fiction, yet now a concrete clinical path is emerging.
How CTX001 works
CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing tool derived from a bacterial defense mechanism. It functions as a programmable system that can target and modify specific DNA sequences, and it also has potential diagnostic applications.
In this case, CTX001 is designed to edit the genes of a patient's own blood cells. The therapy aims to cut out a gene that normally suppresses the production of fetal hemoglobin. In healthy individuals, fetal hemoglobin production is switched off after birth in favor of the adult form. However, in patients with sickle cell disease or beta-thalassemia, the adult hemoglobin is mutated and dysfunctional. By reactivating fetal hemoglobin, the treatment could allow red blood cells to carry oxygen effectively, potentially alleviating symptoms such as fatigue, jaundice, severe pain, and in severe cases, death.
Data from cell and animal experiments, presented by the company at the American Society of Hematology meeting in Atlanta, suggest that CTX001 is highly efficient at editing the target gene and shows no evidence of off-target effects so far.
Caution from the medical community
Despite the promise, some experts urge caution. Dr. Stuart Orkin, a hematologist-oncologist at Boston Children's Hospital, told Chemical & Engineering News that careful execution is essential. He warned that any mistake or adverse effect from CRISPR could have consequences that extend beyond the individual patient, potentially affecting the entire field of gene-editing therapies.
If the trial encounters serious complications, it could deter other companies from pursuing similar studies and may lead regulators to impose stricter oversight. Conversely, a successful outcome—or even a trial that demonstrates safety without major complications—could encourage further innovation, including applications in antibiotic resistance, disease reversal, and eradication of genetic disorders.
The application is now under review by European authorities. No timeline for a decision has been announced, and the company has not disclosed which specific trial sites or patient populations would be involved. The outcome of this regulatory review will be closely watched by researchers, investors, and patient advocacy groups alike.





